南京招聘

Accountabilities :

1. Manage study timelines, objectives and budgets, ensure data accuracy and integrity.
2. Analyze and interpret the data generated during discovery, early and/or full development; responsible for timely and effective communication of data, strategy and results to the project teams.
3. Identify potential project hurdles, suggest solutions and contribute to contingency plans.
4. Coauthor and prepare key preclinical and clinical, and regulatory documents, scientific manuscripts and patent application, including, but not limited to: study protocols, study reports, modeling reports, investigator brochures, IND/IMPDs and NDAs within agreed timelines, and meeting all regulatory requirements.
5. Works collaboratively within cross-departmental teams, department-wide initiatives and work streams.
6. Provide cell therapy expertise on due diligence of BD projects and prepare appropriate documentation.
7. Adhere to the appropriate SOP and GxP guidelines, and embrace a collaborative culture

Qualifications: 

1. PhD and/or MD, strong scientific background in immunology or oncology, international Post-doctoral training is an advantage.
2. Have antibody discovery and characterization experience.
3. Could do virus vector design and optimization
4. He/she is familiar with in vivo animal study, could evaluate drug potency and safety.
5. Extensive knowledge of cell biology and cancer biology, solid scientific publication.
6. Pharmaceutical industry R&D work experience is an advantage

关于复星凯特生物科技有限公司
复星凯特生物科技有限公司为上海复星医药集团与美国 Kite Pharma（吉利德旗下公司）的合营企业， 2017年 4月于中国上海注册成立。立足于自主研发和技术转移相结合，复星凯特致力于肿瘤免疫细胞治疗技的产业化和规范化，造福中国患者。

About Fosun Kite Biotechnology Co., Ltd.
As a joint venture of Shanghai Fosun Pharmaceutical (Group) Co., Ltd and U.S. Kite Pharma, Fosun Kite Biotechnology Co., Ltd. (hereinafter referred as "Fosun Kite") was established in April 2017 in Shanghai China. Taking a combined approach of internal R&D and external partnering/technology transfer, Fosun Kite is dedicated to the advancement of innovative cell therapy and its industrialization in China to benefit patients.